Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Fingolimod – Novel Therapy for Multiple Sclerosis

Drug (Brand/Generic)

Gilenya / Fingolimod

Company / Licensee

Mitsubishi Pharma Corporation/Novartis

Therapy Class

S1P-receptor modulator

Product Description

Binds to the S1P receptor on circulating lymphocytes

Current Indication

Treatment of multiple sclerosis

Market Sector

CNS

Development Status

Approved in the US, Switzerland, Australia and the EU
Expand
Close
Close
Close

Go Top